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Dear EDITOR: The National Institute for Health and Care Excellence (NICE) identified treatment of moderate-to-severe psoriasis as an area for research. [1] [2] No recent studies have assessed treatment patterns and outcomes among patients hospitalised for psoriasis in the UK. [3] [4] [5] This study evaluated clinician-and patient-reported outcomes, treatment patterns, and achieved a ≥5-point DLQI improvement from admission to discharge.
Prior to, during, and post-hospitalisation, topicals were the most frequently used, followed by systemic therapy, phototherapy, and biologics. (Tables 1-2) The mean (range) LOS was 17.0 (2-71) days. For patients achieving PASI75, the mean LOS was 18.1 vs. 13.1 days for those not achieving PASI75. Multivariate regression analyses suggest that (coefficient estimate, p-value) higher PASI at admission (0.27, <0.01), arterial hypertension (7.64, 0.03), and time (months) since diagnosis (0.02, 0.05) contributed to longer LOS.
In recent years, there has been a decline in the number of overnight hospital stays for psoriasis. 7 Treatments received are consistent with NICE and European clinical guidelines recommending phototherapy or systemic therapy in combination with topicals for moderate-tosevere psoriasis. 5, 8, 9 Nevertheless, the proportion of patients prescribed biologics at discharge was lower than expected, since 68% reported a mean PASI or DLQI score >10 at discharge after receiving intensive treatment in the inpatient setting. Our inpatient sample may reflect a more
complex population with difficult-to-control psoriasis, who may be unresponsive or contraindicated to biologics.
Study limitations include the modest sample size, which based on enrolment logs, represented 57% of patients presenting for hospital stays. Clinical differences between enrolled/non-enrolled patients cannot be determined. Also, given the proportion of missing data in some variables, results should be assessed prudently.
This study demonstrated that disease burden and LOS are substantial among hospitalised psoriasis patients. Whilst on average, patients' psoriasis improved in hospital, they still had suboptimal clinician-and patient-reported outcomes at discharge. Further investigation is required to elucidate parallels between the study group and all psoriasis patients and the low use of biologics in our study. Whilst inpatient psoriasis hospitalisations have declined, this study suggests that it remains an important service for a subgroup of patients. Future research may help to alleviate inpatient disease burden, reduce LOS and avoid future hospital admissions through outpatient treatment options.
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